Editorial: Sofosbuvir Plus Daclatasvir for the Treatment of Hepatitis C-Can One Size Fit All?

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14530
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Sofosbuvir Plus Daclatasvir With or Without Ribavirin in 551 Patients With Hepatitis C-Related Cirrhosis, Genotype 4

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

One Size Does Not Fit All

Journal of College Orientation, Transition, and Retention
2019English

Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients After Treatment With Sofosbuvir and Daclatasvir

International Journal of Current Microbiology and Applied Sciences
2018English

Sofosbuvir Plus Ledipasvir for Recurrent Hepatitis C in Liver Transplant Recipients

Liver Transplantation
HepatologyTransplantationSurgery
2017English

Rapamycin – “One Size Does Not Fit All”

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

Decreasing Readmissions: It Can Be Done but One Size Does Not Fit All

BMJ Quality and Safety
MedicineHealth Policy
2013English

Self-Management: One Size Does Not Fit All

Patient Education and Counseling
Medicine
2013English

Revascularization Options: One Size Does Not Fit All

CMAJ
Medicine
2011English

Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir Plus Asunaprevir Treatment

Tohoku Journal of Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy